ReviewJournal of diabetes investigation2022
Non-alcoholic fatty liver disease and type 2 diabetes: An update.
Review in Journal of diabetes investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed.
- The Impact of Low-Volume High-Intensity Interval Training (LV-HIIT) on Fatty Liver Index (FLI) and Estimated Glomerular Filtration Rate (eGFR) in Patients with Type 2 Diabetes Mellitus (T2DM).Current diabetes reviews · 2025Trial
- Evaluation of sleep quality and obstructive sleep apnea in non-alcoholic fatty liver disease: a cross-sectional study.BMC gastroenterology · 2026Article
- Effects of Linagliptin on Liver Enzymes in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2026Review
- The triglyceride to HDL‑C ratio explains part of the association between fatty liver and incident type 2 diabetes: a statistical mediation analysis of the NAGALA cohort.BMC gastroenterology · 2026Article
- Integrated Bulk and Single-Cell RNA-Seq Analysis Reveals Transcriptional Activation of PTGS2 by FOS in Progression From T2DM to T2DM-Associated NAFLD.Journal of cellular and molecular medicine · 2026Article
- Gestational Diabetes Associated with Postpartum NAFLD Risk Meta-Analysis: Evidence for Sustained Metabolic Dysfunction Beyond Pregnancy.Journal of clinical medicine · 2026Review
- Integration ofJHEP reports : innovation in hepatology · 2026Article
- Knowledge, attitude, and practice towards fatty liver disease among the general population in Shanghai, China: a community-based cross-sectional study.Frontiers in public health · 2026Article
- Assessing the association of FIB-4 index with diabetic kidney disease in patients with diabetes mellitus: a cross-sectional and retrospective study utilizing NHANES and clinical data.Frontiers in endocrinology · 2026Article
- Article
- Association of the fibrosis-4 index with prevalent diabetes among adults: a cross-sectional analysis of NHANES 2003-2018 and a Chinese hospital-based health examination population.Frontiers in endocrinology · 2026Article
- From the Liver to Heart in Nonalcoholic Fatty Liver Disease: Single-Cell and Serum Evidence for Cytokeratin 18 in Predicting Cardiovascular Risk.Cardiovascular therapeutics · 2026Article
- Construction and validation of a diagnostic model for type 2 diabetes mellitus comorbid with metabolic dysfunction-associated steatotic liver disease based on routine serological indicators: a retrospective case-control study.Frontiers in endocrinology · 2026Article
- Machine Learning-Based Risk Stratification for Metabolic Dysfunction Severity Among Diabetic Patients With Established MASLD: Distinguishing Normal-Weight From Overweight Individuals.Journal of diabetes research · 2026Article
- Risk assessment of daikenchuto-induced hepatobiliary injury in colon cancer patients post-colectomy: a retrospective cohort study.BMC complementary medicine and therapies · 2025Article
- From fatty liver indices to the Zhejiang University index: Re-shaping risk stratification of metabolic liver disease in diabetes.World journal of diabetes · 2025Article
- The complicated relationship between inflammation and metabolic dysfunction.Journal of diabetes and metabolic disorders · 2025Review
- Integrated bulk and single-cell transcriptomics identify RELB, S100A9, and SOCS1 as key autophagy-endoplasmic reticulum stress genes linking T2DM with MAFLD.Scientific reports · 2025Article
- Exploring the Mechanisms ofInternational journal of molecular sciences · 2025Article
- Association of Elevated Galectin-4 Concentrations with Obesity, Diabetes, and Cardiovascular Diseases.International journal of molecular sciences · 2025Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global prevalence of non-alcoholic fatty liver disease (NAFLD) is rising, along with the epidemic of diabesity. NAFLD is present in >70% of individuals with type 2 diabetes. Although the mutually detrimental relationship between NAFLD and type 2 diabetes has been well established, a multitude of recent studies have further shown that type 2 diabetes is closely linked to the development of cirrhosis, hepatocellular carcinoma, liver-related morbidity and mortality. In contrast, NAFLD also negatively impacts type 2 diabetes both in terms of its incidence and related adverse clinical outcomes, including cardiovascular and chronic kidney diseases. In response to these global health threats, clinical care pathways for NAFLD and guidelines for metabolic dysfunction-associated fatty liver disease have been developed. Several antidiabetic agents have been evaluated for their potential hepatic benefits with promising results. Furthermore, type 2 diabetes patients are increasingly represented in clinical trials of novel therapeutics for NAFLD. However, despite the wealth of knowledge in NAFLD and type 2 diabetes, lack of awareness of the disease and the potential weight of this problem remains a major challenge, especially among clinicians who are outside the field of hepatology and gastroenterology. This review therefore aimed to provide all diabetes care providers with a summary of the latest evidence that supports NAFLD as an emerging diabetic complication of increasing importance, and to present the current recommendations, focusing on the assessment and therapeutic strategies, on the management of NAFLD among type 2 diabetes patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.